United States-based developer, manufacturer and marketer of FDA-approved pharmaceuticals KVK Tech, Inc. announced on Wednesday that it has registered Lomaira™ (phentermine hydrochloride USP) 8mg tablets, CIV in Mexico.
The registration is the result of a strategic partnership with Productos Medix SA de CV, a company involved in pharmaceutical obesity products in Mexico. The licensing agreement provides Medix with a license for the manufacture, distribution, and marketing of Lomaira in Mexico.
Lomaira is an appetite suppressant available by prescription only and used for a short period of time for weight reduction in adults with an initial body mass index (BMI) of 30 or more or 27 or more with a weight-related condition such as controlled high blood pressure, diabetes, or high cholesterol.
Kiran Vepuri, KVK vice president of Business Development, said, 'We're thrilled for Medix to launch Lomaira in Mexico and help tackle the unmet needs in the global obesity epidemic. Obesity is not just an American problem and we aspire to help patients worldwide.'
OnCusp Therapeutics' CUSP06 receives US FDA Fast Track Designation
Telix Pharmaceuticals' Illuccix receives UK regulatory approval
MimiVax reports positive interim analysis of SurVaxM Phase 2b clinical trial
Akeso enrols first patient in cadonilimab Phase 3 clinical trial
AbbVie and Xilio Therapeutics announce collaboration to develop tumour-activated immunotherapies
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Oxford BioDynamics announces distribution agreement with Regina Maria for EpiSwitch tests in Romania
Lytix Biopharma secures US patent allowance for LTX-315 clinical programme
GenSight Biologics reports positive five-year resultsfor LUMEVOQ gene therapy
Health Canada approves Merck's KEYTRUDA for resectable non-small cell lung cancer
Owens & Minor launches ByramConnect digital health platform for diabetes management
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
NLS Pharmaceutics and Kadimastem plan multi-target approach to diabetes
Hoth Therapeutics and OnTargetx R&D partner on cancer research
CStone Pharmaceuticals' Cejemly included in ESMO NSCLC Living Guideline